521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

Co-Author(s)

• SA

  Soo Aleman, MD, PhD

  Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden
  Stockholm, Sodermanlands Lan, Sweden
• HW

  Heiner Wedemeyer, MD, PhD

  Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
  Hannover, Niedersachsen, Germany
• MB

  Maurizia Brunetto, MD

  Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  Pisa, Toscana, Italy
• AB

  Antje Blank, MD

  Medical Faculty Heidelberg/Heidelberg University Hospital, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany
  Heidelberg, Baden-Wurttemberg, Germany
• PA

  Pietro Andreone, PhD

  University of Modena and Reggio Emilia, Internal Medicine, Baggiovara Hospital
  Modena, Emilia-Romagna, Italy
• 

  Pavel Bogomolov, MD, Ph.D (he/him/his)

  Head of hepatology dept.
  M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
  Moscow, Moskva, Russia
• VC

  Vladimir Chulanov, MD, PhD

  Sechenov University
  Moscow, Moskva, Russia
• NM

  Nina Mamonova, MD

  FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
  Moscow, Moskva, Russia
• NG

  Natalia Geyvandova, PhD

  Stavropol Regional Hospital
  Stavropol, Stavropol', Russia
• VM

  Viacheslav Morozov, MD, PhD

  LLC Medical Company Hepatolog, Samara, Russian Federation
  Samara, Samara, Russia
• OS

  Olga Sagalova, MD, PhD

  South Ural State Medical University, Chelyabinsk, Russian Federation
  Chelyabinsk, Moskva, Russia
• TS

  Tatyana Stepanova, MD

  LLC Clinic of Modern Medicine, Moscow, Russian Federation
  Moscow, Moskva, Russia

Co-Author(s)

• GC

  Grace Chee, PharmD

  Gilead Sciences, Inc.
  Foster City, California, United States

Rapid Fire Presenter(s)

• 

  Dmitry Manuilov, MD

  Sr. Director, Virology Clinical Development
  Gilead Sciences, Inc.
  Foster City, California, United States

Co-Author(s)

• ML

  Mingyang Li, PhD

  Gilead Sciences, Inc.
  Foster City, California, United States
• AL

  Audrey Lau, MD, PhD

  Gilead Sciences, Inc.
  Foster City, California, United States
• AO

  Anu Osinusi, MD

  Clinical Research
  Gilead
  Foster City, California, United States
• ST

  Steve Tseng, MD

  Gilead Sciences, Inc.
  Foster City, California, United States
• JS

  Julian Schulze Zur Wiesch, MD, PhD

  Hepatology Outpatient Medical Clinic, University Hospital Hamburg-Eppendorf, Hamburg, Germany
  Hannover, Niedersachsen, Germany
• MC

  Markus Cornberg, MD, PhD

  Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
  Hannover, Niedersachsen, Germany
• SZ

  Stefan Zeuzem, MD, PhD

  Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany
  Frankfurt, Hessen, Germany
• PL

  Pietro Lampertico, MD

  CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan
  Milan, Lombardia, Italy